BTI: Velo Is Bigger Than The Street Thinks — Buy the Reopening of Growth

Hook / Thesis

British American Tobacco (ticker: BTI) is a classic income name that also carries a disguised growth option: Velo and other oral nicotine pouches. At $52.86, the stock sits well below its 52-week high of $67.30 and near the lower part of its 52-week band, but the combination of a 6%+ dividend yield and a pathway to outsized category growth argues for a long trade. The market is pricing BTI largely as a legacy cigarette play; we think smoke-free formats deserve higher multiple as they scale.

Our trade idea: buy BTI at an entry of $52.86$49.00, and target $68.00 over a long-term horizon (180 trading days). This captures upside from stronger-than-expected pouch adoption, improved margins as scale catches up, and re-rating as investors reward recurring revenue with secular growth.

What BTI does and why Velo matters

British American Tobacco is a global tobacco manufacturer with major brands including Kent, Dunhill, Lucky Strike and Pall Mall, and a growing smoke-free portfolio that includes the Velo oral nicotine pouch. The company operates across the United States, Americas and Europe (AME), and Asia-Pacific, Middle East & Africa (APMEA). For income investors, BTI pays a quarterly dividend — the most recent distribution per share is $0.824851 and the stock yields roughly 6.07%. Ex-dividend date was 10/02/2026 and payable date is 11/12/2026.

Why should the market care about Velo? Oral nicotine pouches are one of the fastest-growing tobacco-adjacent categories. Independent reporting projects the oral nicotine pouch market to grow from $5.4 billion in 2024 to over $25 billion by 2030. If BTI captures a meaningful share of that expansion, the growth profile of the company moves from slow organic cash flow to a faster, higher-margin expansion story. That shift is precisely what could push multiples higher.

Evidence & numbers behind the thesis

The market snapshot shows a company with healthy scale and a defensive cash return profile: market capitalization sits at approximately $113.7 billion, trailing P/E is about 13.41, and price-to-book is roughly 1.78. Shares outstanding are ~2.15 billion and float is ~2.15 billion, which supports liquidity — average volume is roughly 4.57 million shares (2-week average) and 5.41 million over 30 days.

On the tape, technicals look constructive for a mean reversion trade: current price $52.86 is below the 10-, 20- and 50-day SMAs ($54.73, $55.22 and $56.71 respectively) and the RSI is near 32, indicating near-oversold conditions. MACD shows bearish momentum but the magnitude is modest, leaving room for a bounce if fundamental catalysts materialize.

Valuation framing

At a market cap of $113.7B and P/E ~13.4, BTI trades like a slow-decline cash generator rather than a company with a clear growth optionality. If Velo and other smoke-free formats can grow revenue contribution and deliver higher incremental margins, a 2-3 point multiple expansion is realistic. For context, the stock’s 52-week range is $49.88 - $67.30; our target of $68.00 implies a re-test (and slight exceed) of prior highs, which is reasonable if Velo performance beats expectations and headline net revenue growth re-accelerates.

Put another way: the company’s dividend (recent quarterly dividend $0.824851) and yield (>6%) create a floor that many defensive investors respect. That defensive floor plus the optional upside from Velo presents an attractive asymmetric trade: limited downside to the dividend buffer, substantial upside if smoke-free adoption accelerates and the market re-rates the growth component.

Catalysts (that could drive the trade)

• Accelerating Velo rollouts in core markets and improved share gains versus peers; visible shipment/market share prints in quarterly updates.
• Quarterly results that show smoke-free revenue contribution rising and gross margins improving on scale.
• Investments and partnerships in adjacent categories - for example, BTI’s participation in the Organigram deal in Europe signals willingness to fund adjacent growth streams and expand distribution partnerships.
• Positive regulatory or labeling clarity that eases consumer adoption or lowers trade barriers in large markets.
• Macro rotation back into high-yield, defensive names during periods of market stress, supporting valuation multiple expansion.

Trade plan

Entry: $52.86 (current price).
Stop loss: $49.00 — below the recent 52-week low of $49.88 and under the psychological $50 handle; a close below $49 would suggest structural weakness and increased downside risk.
Target: $68.00 — slightly above the 52-week high, capturing a re-rating if Velo proves it can materially shift growth expectations and margins.
Risk level: medium. This trade pays a healthy dividend while banking on execution in a higher-growth category; execution risk exists but is balanced by income support.

Horizon: long term (180 trading days). We expect it will take multiple quarterly reports and the steady buildup of retail share to convince investors the Velo story is real. If Velo acceleration shows up in one or two consecutive quarters, the move to $68 can happen faster; however, give the trade roughly 6-9 months to play out to allow for quarter-to-quarter evidence and sentiment adoption.

Alternative approach: scale in with a two-leg buy — 50% at current price and 50% on weakness into $50.00 - $51.00 to lower cost basis while keeping the same stop at $49.00.

Key points to watch

• Quarterly smoke-free revenue growth and margin trends.
• Market share prints for oral nicotine pouches in the U.S. and EU.
• Management commentary on pricing power, costs and marketing spend for Velo.
• Regulatory developments or tax changes affecting nicotine products.

Risks and counterarguments

Counterargument: The simplest rebuttal is that cigarette declines will outpace Velo adoption. Cigarettes still generate the bulk of profit and pricing power, and if smoking volumes deteriorate faster than pouch uptake, the company’s headline growth could slow and multiples could compress further.

• Regulatory risk: Tighter restrictions on nicotine pouches — packaging, flavor bans, or higher taxes — would directly reduce addressable market and growth expectations.
• Competitive risk: Altria, Philip Morris and regional players are all pursuing pouches and could defend share through pricing, distribution or superior local marketing.
• Execution risk: Consumer behavior doesn’t shift as expected; Velo uptake stalls or margins remain pressured by promotional activity and higher marketing costs.
• Macro/dividend pressure: A deep market downturn or stress on cash flows could force management to slow buybacks or reduce dividends; the 6%+ yield is attractive but not immune to cuts under extreme scenarios.
• FX and geographic exposure: Significant operations in multiple regions mean currency moves or regional recessions can reduce reported revenue and margins.

What would change my mind

I would abandon the bullish stance if two or more of the following occur: (1) quarterly data show persistent failure to grow smoke-free revenue on a sequential basis; (2) regulatory actions substantially increase taxes or restrictions on pouches in key markets; (3) management explicitly signals a change in capital allocation towards defensive cash preservation that includes a dividend cut; or (4) net margin compression across the group tied to sustained promotional wars in the pouch category.

Conclusion

BTI is a pragmatic buy here for patient, income-oriented investors who want a defined-risk way to play the transition to smoke-free nicotine. The trade combines a strong dividend floor with asymmetric upside from Velo scaling and re-rating potential. Entry at $52.86, stop at $49.00, and target at $68.00 over a long-term horizon (180 trading days) gives a concrete, actionable plan. Expect the path to be choppy — watch share gains and margin progress closely — but the risk/reward looks attractive if smoke-free adoption continues on its current trajectory.

Quick reference table

For readers who want the instrument metadata, BTI's instrument endpoint is included in public filings: instrument link.